RxDoctor Payments Data

Michael Driscoll, MD

Medical Oncology · Louisville, KYNPI 1891824587

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.1% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AstraZeneca at 28.3% of the total. Reporting peaked in 2024 at $1,189 and has fallen 58.0% since, to $499 in 2025. That places this record below the midpoint for medical oncology clinicians in KY, where the typical reported total is $3,396.

$2,485in general payments, 2019–2025

Across 31 payments — averaging $80.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$702
  • Amgen$324
  • Genentech, Inc.$263
  • Jazz Pharmaceuticals Inc.$235
  • Takeda Pharmaceuticals U.S.A., Inc.$185
  • Genentech USA, Inc.$145
  • plus $631 from 9 others
$3,574,099in research payments, 2019–2025

Across 181 payments — averaging $19,746 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$2.3M
  • Seagen Inc.$624K
  • Merck$229K
  • AstraZeneca$115K
  • Daiichi Sankyo Inc.$107K
  • Genentech, Inc.$102K
  • plus $95K from 4 others

What the payments were for

  • Food & beverage$2,46299%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,485 in reported general payments places this provider in the 45th percentile of 53 medical oncology providers in Kentucky.

See all medical oncology providers in Kentucky

Medicare billing

Part B allowed, 2024
$212,518
Medicare patients
499
Services billed
2,481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide36$589,591
VerzenioAbemaciclib23$346,126
TasignaNilotinib Hcl12$236,360
XtandiEnzalutamide13$183,447
BrukinsaZanubrutinib13$156,706
EliquisApixaban138$116,418
CreonLipase/Protease/Amylase19$49,557
Ondansetron Hcl105$4,993
Fentanyl34$4,084
Morphine Sulfate ErMorphine Sulfate70$3,489
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen122$3,474
Oxycodone Hcl104$1,938
Anastrozole94$1,580
Exemestane20$1,545
Hydroxyurea20$1,000

Paid to pharmacies, not to this prescriber.

Other medical oncology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →